Market Overview:
The global plasma fraction market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, rising demand for plasma-derived products, and technological advancements in the field of plasma fractionation. Based on type, the global plasma fraction market is segmented into protease inhibitors, proteases, fibrinolytic proteins, coagulation factors, and anti-coagulant proteins. The protease inhibitors segment is expected to grow at a CAGR of 6.0% from 2018 to 2030 due to the increasing demand for these products across hospitals and clinics worldwide. Based on application, the global plasma fraction market is divided into hospitals, clinics, ambulatory surgical centers (ASCs), and others (research institutes). The hospitals segment accounted for majority share of 43% in 2017 owing to rising number of surgeries performed in this setting globally. Geographically speaking North America held dominant position with around 38% share followed by Europe with nearly 31%.
Product Definition:
A plasma fraction is a medical treatment that separates blood components into different parts. One component, the plasma, is extracted and then given back to the person. The other components are either discarded or used in other treatments. Plasma fractions are important because they can help improve the health of people with serious illnesses or injuries.
Protease Inhibitors:
Protease inhibitors are a group of drugs that prevent the action of proteases (enzymes) that digest protein. The most common type of protease inhibitor used in clinical medicine is indomethacin, which is a non-steroidal anti-inflammatory drug (NSAID).
Protease:
Protease is an enzyme that acts as a catalyst in the hydrolysis of protein. Proteinases are used for protein fractionation to separate them from other biological molecules such as nucleic acids and fats. Protease enzymes find applications in various industries including pharmaceuticals, biotechnology, food & beverage and research institutes among others.
Application Insights:
The market is segmented by application into hospitals, clinics and ambulatory surgical centers. The clinics segment dominated the overall industry in terms of revenue in 2017 owing to a high prevalence of chronic diseases such as cancer, diabetes and cardiovascular diseases. Plasma fractionation therapy is an effective treatment for these conditions due to its ability to reduce blood coagulation thereby enabling efficient healing. Moreover, increasing awareness about advanced therapies coupled with rising demand for minimally invasive surgeries has been contributing significantly towards the growth of this segment over the recent years.
On the other hand, hospital based treatments are considered more cost-effective than outpatient procedures due to lower personnel costs involved in hospital care as compared with medical office visits or emergency room visits. This factor along with others such as favorable reimbursement policies by government agencies & private insurance companies will continue driving demand from hospitals over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-developed healthcare infrastructure and high adoption rate for advanced therapeutics are some factors responsible for its large share. Moreover, increasing prevalence of cardiovascular diseases, cancer, diabetes is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising geriatric population and growing disposable income coupled with improving healthcare facilities in emerging countries such as China and India. Furthermore, government initiatives encouraging R&D activities are also expected to boost product penetration across this region during the forecast period ‰â€˜â€˜â€˜ ’ ’ â”' &%$#$@#%!'!"#$%"&'()*+,-.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. Chronic diseases are characterized by long-term, persistent symptoms and require ongoing treatment. Plasma fraction therapy is increasingly being used to treat a wide range of chronic diseases, including cancer, autoimmune disorders, and genetic disorders.
- Growing demand for personalized medicine: The field of personalized medicine is growing rapidly as patients become more aware about the benefits offered by customized therapies and treatments. Plasma fraction therapy offers great potential for customization depending on the specific needs of each patient. This has led to an increase in demand for plasma fraction products from both healthcare providers and patients alike.
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasma Fraction Market Research Report
By Type
Protease Inhibitors, Protease, Fibrinolytic Proteins, Coagulation Factors, Anti-Coagulant Proteins
By Application
Hospitals, Clinics, Ambulatory Surgical Centers
By Companies
Baxter, Octapharma, Biotest, CSL, Grifols, Kedrion, LFB, Chinese Biological Products, Shanghai RAAS Blood Products
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
149
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Plasma Fraction Market Report Segments:
The global Plasma Fraction market is segmented on the basis of:
Types
Protease Inhibitors, Protease, Fibrinolytic Proteins, Coagulation Factors, Anti-Coagulant Proteins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Octapharma
- Biotest
- CSL
- Grifols
- Kedrion
- LFB
- Chinese Biological Products
- Shanghai RAAS Blood Products
Highlights of The Plasma Fraction Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Protease Inhibitors
- Protease
- Fibrinolytic Proteins
- Coagulation Factors
- Anti-Coagulant Proteins
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasma Fraction Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasma fraction is a measure of the concentration of plasma proteins in a sample.
Some of the major companies in the plasma fraction market are Baxter, Octapharma, Biotest, CSL, Grifols, Kedrion, LFB, Chinese Biological Products, Shanghai RAAS Blood Products.
The plasma fraction market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Plasma Fraction Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Plasma Fraction Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Plasma Fraction Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Plasma Fraction Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Plasma Fraction Market Size & Forecast, 2020-2028
4.5.1 Plasma Fraction Market Size and Y-o-Y Growth
4.5.2 Plasma Fraction Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Protease Inhibitors
5.2.2 Protease
5.2.3 Fibrinolytic Proteins
5.2.4 Coagulation Factors
5.2.5 Anti-Coagulant Proteins
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Plasma Fraction Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Plasma Fraction Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Protease Inhibitors
9.6.2 Protease
9.6.3 Fibrinolytic Proteins
9.6.4 Coagulation Factors
9.6.5 Anti-Coagulant Proteins
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Protease Inhibitors
10.6.2 Protease
10.6.3 Fibrinolytic Proteins
10.6.4 Coagulation Factors
10.6.5 Anti-Coagulant Proteins
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Protease Inhibitors
11.6.2 Protease
11.6.3 Fibrinolytic Proteins
11.6.4 Coagulation Factors
11.6.5 Anti-Coagulant Proteins
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Protease Inhibitors
12.6.2 Protease
12.6.3 Fibrinolytic Proteins
12.6.4 Coagulation Factors
12.6.5 Anti-Coagulant Proteins
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Protease Inhibitors
13.6.2 Protease
13.6.3 Fibrinolytic Proteins
13.6.4 Coagulation Factors
13.6.5 Anti-Coagulant Proteins
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Plasma Fraction Market: Competitive Dashboard
14.2 Global Plasma Fraction Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter
14.3.2 Octapharma
14.3.3 Biotest
14.3.4 CSL
14.3.5 Grifols
14.3.6 Kedrion
14.3.7 LFB
14.3.8 Chinese Biological Products
14.3.9 Shanghai RAAS Blood Products
